Leishmania is a unicellular protozoan that has a limited transcriptional control and mostly
uses post-transcriptional regulation of gene expression, although the molecular …

Background One of the major challenges to leishmaniasis treatment is the emergence of
parasites resistant to antimony. To study differentially expressed genes associated with drug …

Antimonials (Sb) were used for decades for chemotherapy of visceral leishmaniasis (VL).
Now abandoned in the Indian subcontinent (ISC) because of Leishmania donovani …

Leishmaniasis represents a serious health problem worldwide and drug resistance is a
growing concern. Leishmania parasites use unusual mechanisms to control their gene …

Leishmaniasis causes significant morbidity and mortality worldwide. The disease is endemic
in developing countries of tropical regions, and in recent years economic globalization and …

Leishmaniasis is a vector-borne parasitic disease caused by Leishmania parasites with a
spectrum of clinical manifestations, ranging from skin lesions to severe visceral …

Antimonials are still the mainstay of treatment against leishmaniasis but drug resistance is
increasing. We carried out short read next‐generation sequencing (NGS) and comparative …

Antimonials remain the first line drug against the protozoan parasite Leishmania but their
efficacy is threatened by resistance. We carried out a RNA expression profiling analysis …

Antimony-based drugs are still the mainstay of chemotherapy against Leishmania infections
in many countries where the parasites are endemic. The efficacy of antimonials has been …

Resistance to antimony is a major cause of failure to therapy in a large proportion of visceral
leishmaniasis cases. Methods to distinguish resistant and sensitive parasite are urgently …